Navigation Links
Favorable Scenario for Japan Pharma Industry in Coming Years, New Report Says

(PRWEB) February 28, 2013

The coming years will see Japan pharma regaining its status as innovator driven with Edoxaban for Daiichi Sankyo, Canagliflozin for Mitsubishi Tanabe, and Dolutegravir for Shionogi bringing the good times back for the respective companies in 2013 and carrying enough potential to change global market dynamics in the anticoagulant, diabetes and HIV space resp. The massive $45b poured in acquiring innovation by Japanese companies does not justify its value as the key catalysts from Japan are in-house candidates.

Changing political scenario in Japan will accelerate the pace of reforms in Japan as recently; the Liberal Democratic Party (LDP) of Japan came back into power replacing the short tenure of the Democratic Party of Japan (DPJ). LDP was the pioneer initiator of major healthcare reforms with a focus on curbing healthcare costs by means of enhancing generic drugs penetration. This report discusses in details about the implications of these changes on Innovator and generic domestic Japanese pharma companies.

Global companies on the other hand are going to see a favorable scenario in coming years - expected launches in 2013-2014 from global companies will increase competition to domestic players mainly in the respiratory, oncology and rheumatoid arthritis therapy areas, and will increase overall market size of Diabetes and Osteoporosis markets.

Going forward, generic companies will continue to witness a growth story.

Leading players featured in this report include Daiichi Sankyo, Kyorin, Mitsubishi Tanabe, Shionogi, Eisai, Astellas, Chugai, Dainippon Sumitomo, Kyowa Hakko Kirin, Nippon Chemiphar, Sawai, Takeda, and Towa.

For more information please visit

Research and Markets
Laura Wood, Senior Manager.
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Sector: Biotechnology

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. OrbusNeichs Combo Dual Therapy Stentâ„¢ Demonstrates Favorable Clinical and Safety Outcomes at 12-Month Follow-Up
2. Spectrometry Market (Atomic, Molecular and Mass Spectrometry) - Global Scenario, Trends, Industry Analysis, Size, Share & Forecast 2011 - 2017
3. CoreLab Partners Opens Office in Tokyo, Japan
4. Generex Announces Patent Award for its Core Vaccine Technologies in Japan
5. Regulus Receives Allowance from Japan and U.S. Patent Offices for HCV Intellectual Property, Expanding Leading Worldwide Patent Estate
6. Immunomic Therapeutics Receives IND Authorization for Phase I Study of JRC-LAMP-Vax Vaccine to Treat Japanese Red Cedar (Sugi) Allergy
7. Life Technologies Signs Licensing Agreement with iPS Academia Japan for Global Patent Portfolio Rights to Induced Pluripotent Stem Cell Technology
8. Snoasis Medical Initiates Distribution in Japan Through Hausten Healthcare
9. First Baby With Artificial Heart in Japan
10. Sosei Group Corporation QVA149 Phase III Study Meets Primary Endpoint in Reducing Exacerbations in COPD Patients and Filings in EU and Japan by End of Year
11. Japan Bioinformatics Announces Study on Leading Mapping Tools for DNA Mutation Discovery
Post Your Comments:
(Date:11/24/2015)... SAN DIEGO , Nov. 24, 2015 Halozyme Therapeutics, ... Jaffray Healthcare Conference in New York on ... Dr. Helen Torley , president and CEO, will provide a ... New York at 1:00 p.m. ET/10:00 a.m. ... communication and investor relations, will provide a corporate overview. --> ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris ... of IIROC on behalf of the Toronto Stock Exchange, ... release there are no corporate developments that would cause ... --> --> About Aeterna ... . --> Aeterna Zentaris is a ...
(Date:11/24/2015)... IN (PRWEB) , ... November 24, 2015 , ... The ... newest Special Interest Group (SIG), MultiGP, also known as Multirotor Grand Prix, to represent ... the last few years. Many AMA members have embraced this type of racing and ...
(Date:11/24/2015)... QUEBEC CITY , Nov. 24, 2015 /PRNewswire/ ... (the "Company") announced today that the remaining 11,000 ... Common Share Purchase Warrants (the "Series B Warrants") ... agreement were exercised on November 23, 2015, which ... Common Shares.  After giving effect to the issuance ...
Breaking Biology Technology:
(Date:11/19/2015)... NEW YORK , Nov. 19, 2015  Although ... the market is dominated by a few companies, according ... Qiagen. These companies own 51% of the market share of ... report, The World Market for Molecular Diagnostic ... "The market is still controlled by one ...
(Date:11/17/2015)... 2015  Vigilant Solutions announces today that Mr. ... Directors. --> --> ... the partnership at TPG Capital, one of the largest ... Billion in revenue.  He founded and led TPG,s Operating ... companies, from 1997 to 2013.  In his first role, ...
(Date:11/12/2015)... 11, 2015   Growing need for low-cost, ... has been paving the way for use of ... discrete analytes in clinical, agricultural, environmental, food and ... used in medical applications, however, their adoption is ... to continuous emphasis on improving product quality and ...
Breaking Biology News(10 mins):